SEOUL, January 15 (AJP) - SK Biopharm announced plans to establish a joint venture with Brazilian pharmaceutical giant Eurofarma in the United States, the South Korean firm said at the JP Morgan Healthcare Conference on Jan. 14.
The venture will focus on commercializing an artificial intelligence-based epilepsy management platform in North America. This platform leverages SK Biopharm's AI technology for brain wave analysis and wearable devices developed since 2018.
The remote epilepsy treatment market is projected to reach $1.8 billion by 2032, with North America accounting for a significant portion.
The joint venture in the U.S. will utilize SK Biopharm's existing network of healthcare providers, built through the direct sales of its epilepsy drug cenobamate.
The AI-powered solution will provide real-time monitoring of epileptic seizures and support healthcare providers in developing data-driven treatment plans, said SK Biopharm CEO Lee Dong-hoon at the conference.
"This collaboration with Eurofarma marks a new chapter in SK Biopharm's global expansion," Lee said, adding his company will develop the venture into a new growth engine for the company.
Copyright ⓒ Aju Press All rights reserved.